ASX - Delayed Quote AUD

Neurizon Therapeutics Limited (NUZ.AX)

0.1250

0.0000

(0.00%)

At close: January 31 at 3:39:10 PM GMT+11

Neurizon Files IND Application to Support HEALEY ALS Platform Trial

(ASX: NUZ & NUZOA) ("Neurizon" or "the Company"), a clinical-stage biotech company advancing treatments for neurodegenerative diseases, is pleased to announce the filing of an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) for its lead candidate, NUZ-001. This milestone is a pivotal step in enabling the commencement of a Phase 2/3 clinical trial within the HEALEY ALS Platform Trial framework. The FDA has a period of 30 days to review the IND application

PR Newswire last month

NUZ.AX
0.00%
NUZOA.AX
Neurizon's NUZ-001 Reduces Aggregation of Key ALS Disease Target TDP-43 in Preclinical Study

Neurizon Therapeutics Limited (ASX: NUZ & NUZOA) ("Neurizon" or "the Company"), a clinical-stage biotech company advancing treatments for neurodegenerative diseases, is pleased to announce positive results from a preclinical study of its lead candidate, NUZ-001. These innovative studies reveal NUZ-001's unique mechanism of action in preventing the aggregation of TAR DNA-binding protein 43 (TDP-43), a key pathological feature of ALS, and the ability of NUZ-001 to significantly improve the electro

PR Newswire 2 months ago

NUZ.AX
0.00%
NUZOA.AX
Neurizon Therapeutics Receives Positive Opinion on Orphan Medicinal Product Designation for NUZ-001 in Europe

Neurizon Therapeutics Limited (ASX: NUZ & NUZOA) ("Neurizon" or "the Company"), a clinical-stage biotech company advancing treatments for neurodegenerative diseases, is pleased to announce it has received notice of a positive opinion from the European Medicines Agency (EMA) for Orphan Medicinal Product Designation (OMPD) following its application for its lead drug candidate, NUZ-001, for the treatment of Amyotrophic Lateral Sclerosis (ALS). The European Commission is scheduled to issue the offic

PR Newswire 2 months ago

NUZ.AX
0.00%
NUZOA.AX
PharmAust affirms corporate strategy with name change to Neurizon Therapeutics

Neurizon Therapeutics Limited (ASX: NUZ) ("Neurizon" or "the Company"), a clinical-stage biotech company dedicated to advancing treatments for neurodegenerative diseases, is pleased to announce it has officially changed its name from PharmAust Limited, to Neurizon Therapeutics Limited. The name change was approved by shareholders at the Company's Annual General Meeting held on 9 October 2024. The new name has been registered with the Australian Securities and Investments Commission (ASIC).

PR Newswire 3 months ago

NUZ.AX
0.00%
PAA.AX

PAAOA.AX

Performance Overview

Return	NUZ.AX	S&P/ASX 200 [XJO]
YTD	-26.47%	+4.57%
1-Year	-34.21%	+11.09%
3-Year	-34.21%	+22.39%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Neurizon Therapeutics Limited (NUZ.AX)

Neurizon Files IND Application to Support HEALEY ALS Platform Trial

Neurizon's NUZ-001 Reduces Aggregation of Key ALS Disease Target TDP-43 in Preclinical Study

Neurizon Therapeutics Receives Positive Opinion on Orphan Medicinal Product Designation for NUZ-001 in Europe

PharmAust affirms corporate strategy with name change to Neurizon Therapeutics

Performance Overview